Breaking News

Pfizer, BioNTech Adapt COVID Vax Against Omicron

Preliminary lab studies demonstrate candidates neutralize Omicron BA.4 and BA.5 though to a lesser extent than they do for BA.1

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer and BioNTech announced data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted vaccine candidates elicited a higher immune response against Omicron BA.1 as compared to the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters